Co announces FDA and European CE Mark approvals to expand the capabilities of its Frontier II cardiac resynchronization therapy pacemaker to include QuickOpt Timing Cycle Optimization, giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback